Eisai and Biogen are moving ahead with late-stage clinical trials of BAN2401, the pair's Alzheimer’s disease drug. The two are working with regulators to design the next studies and gain expedited review as a breakthrough therapy.
Although the drug failed during an earlier stage, it slowed Alzheimer’s progression at its highest dose. After 18 months of treatment, patients who received the highest dose saw a statistically significant improvement in cognitive and biological measures of Alzheimer’s versus placebo.
The companies full results will be presented on at the Alzheimer’s Association International Conference in Chicago.
Read the Eisai release